STOCK TITAN

Cerus (NASDAQ: CERS) shares preliminary 2025 product revenue and outlook

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Cerus Corporation reported that it has released preliminary product revenue results for the fourth quarter and full year ended December 31, 2025, along with an outlook, through a press release referenced in this report. These figures are described as preliminary, unaudited and subject to completion of the company’s normal financial closing procedures, and the final results may differ from these early estimates, with any differences potentially being material.

The company notes that its independent registered public accounting firm has not audited or reviewed these preliminary numbers and does not provide any assurance on them. Cerus emphasizes that the product revenue information should not replace full financial statements prepared under U.S. GAAP and cautions against placing undue reliance on the preliminary data. The information in this report and the accompanying press release is being furnished, rather than filed, and is not automatically incorporated into other SEC filings.

Positive

  • None.

Negative

  • None.
false000102021400010202142026-01-112026-01-11

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2026

 

 

CERUS CORPORATION

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-21937

68-0262011

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1220 Concord Avenue, Suite 600

 

Concord, California

 

94520

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 925 288-6000

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CERS

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On January 11, 2026, Cerus Corporation (the “Company”) announced its preliminary product revenue results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the Company’s press release, entitled “Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook,” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

 

Such product revenue results as reported are preliminary, unaudited and subject to completion. The Company’s independent registered public accounting firm has not audited or performed any procedures with respect to these preliminary results and does not express an opinion or any other form of assurance with respect thereto. The Company’s financial closing procedures for the three months and year ended December 31, 2025 are not yet complete and, as a result, the final results upon completion of the closing procedures may vary from the preliminary estimates, and any such differences may be material. The Company’s product revenue information presented herein should not be viewed as a substitute for the information set forth in the full financial statements prepared in accordance with U.S. generally accepted accounting principles, and undue reliance should not be placed on these preliminary product revenue results.

 

The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this report:

99.1 Press release, dated January 11, 2026, entitled “Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook.”

104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CERUS CORPORATION

 

 

 

 

Date:

January 11, 2026

By:

/s/ Kevin D. Green

 

 

 

Kevin D. Green
Chief Financial Officer

 


FAQ

What did Cerus Corporation (CERS) disclose in this 8-K filing?

Cerus Corporation disclosed that it announced preliminary product revenue results for the fourth quarter and full year ended December 31, 2025, and provided an outlook via a press release furnished as Exhibit 99.1.

Are Cerus Corporation’s preliminary 2025 product revenue results audited?

No. The company states that the reported product revenue results are preliminary and unaudited, and that its independent registered public accounting firm has not audited or performed procedures on these figures.

Can Cerus Corporation’s preliminary product revenue results for 2025 change?

Yes. Cerus explains that its financial closing procedures for the three months and year ended December 31, 2025 are not yet complete, and the final results may vary from the preliminary estimates, with any differences potentially being material.

Does Cerus Corporation consider the preliminary product revenue information a substitute for full financial statements?

No. Cerus states that the preliminary product revenue information should not be viewed as a substitute for full financial statements prepared in accordance with U.S. GAAP and cautions against placing undue reliance on the preliminary results.

Is the information in this Cerus Corporation 8-K considered filed with the SEC?

The company specifies that the information in this report, including the exhibit, is being furnished rather than filed and is not subject to certain liability provisions, nor is it incorporated by reference into other SEC filings unless specifically referenced.

What exhibit is included with Cerus Corporation’s 8-K on preliminary 2025 revenue?

The filing includes Exhibit 99.1, a press release dated January 11, 2026 titled “Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook,” and Exhibit 104, the cover page interactive data file in inline XBRL format.
Cerus

NASDAQ:CERS

CERS Rankings

CERS Latest News

CERS Latest SEC Filings

CERS Stock Data

526.32M
185.71M
3.34%
73.82%
3.6%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
CONCORD